Transcat (TRNS) Expected to Post Quarterly Earnings on Tuesday

Transcat (NASDAQ:TRNS) will likely be issuing its Q1 2027 results after the market closes on Tuesday, August 4th. Analysts expect Transcat to post earnings of $0.37 per share and revenue of $86.42 million for the quarter. Individuals can check the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Transcat (NASDAQ:TRNS) last issued its earnings results on Tuesday, May 26th. The scientific and technical instruments company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. The firm had revenue of $89.33 million for the quarter, compared to analysts’ expectations of $89.79 million. Transcat had a return on equity of 5.84% and a net margin of 1.62%. On average, analysts expect Transcat to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Transcat Price Performance

Transcat stock opened at $86.14 on Tuesday. The company has a current ratio of 2.33, a quick ratio of 1.99 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $806.27 million, a P/E ratio of 148.52 and a beta of 0.69. The business has a 50-day moving average of $87.11 and a 200-day moving average of $78.13. Transcat has a 1 year low of $50.23 and a 1 year high of $95.22.

Hedge Funds Weigh In On Transcat

Several institutional investors and hedge funds have recently modified their holdings of TRNS. Lazard Asset Management LLC acquired a new stake in Transcat during the 2nd quarter worth approximately $54,000. Tower Research Capital LLC TRC boosted its holdings in shares of Transcat by 245.5% in the second quarter. Tower Research Capital LLC TRC now owns 1,123 shares of the scientific and technical instruments company’s stock valued at $97,000 after buying an additional 798 shares during the period. Marshall Wace LLP acquired a new position in shares of Transcat in the fourth quarter valued at approximately $236,000. Balyasny Asset Management L.P. acquired a new position in shares of Transcat in the fourth quarter valued at approximately $247,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Transcat by 8.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,265 shares of the scientific and technical instruments company’s stock worth $299,000 after acquiring an additional 432 shares in the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TRNS shares. Wall Street Zen raised shares of Transcat from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. Zacks Research raised shares of Transcat from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded shares of Transcat from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $105.50.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.

In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.